Kyverna Therapeutics (KYTX) Other financing activities (2023 - 2026)
Kyverna Therapeutics (KYTX) posted Other financing activities of $243000.0 for Q1 2026, down 87.77% on a QoQ basis from $2.0 million in Q4 2025, and up 8000.0% year-over-year from $3000.0 in Q1 2025.
Kyverna Therapeutics (KYTX) Other financing activities (2023 - 2026) Analysis & Trends
Kyverna Therapeutics' Other financing activities history runs 4 years deep, the most recent figure standing at $243000.0 for Q1 2026.
- Quarterly Other financing activities rose 8000.0% year-over-year to $243000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 74133.33% YoY) and the FY2025 annual result came in at $2.0 million, down 99.42% from the prior year.
- Other financing activities was $243000.0 for Q1 2026 at Kyverna Therapeutics, down from $2.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $341.2 million in Q1 2024 and bottomed at -$341.0 million in Q2 2024.
- A 4-year average of $28.7 million and a median of $166500.0 in 2024 frame the typical range for Other financing activities.
- Peak annual rise in Other financing activities reached 1421445.83% in 2024, while the deepest fall reached 947416.67% in 2024.
- Kyverna Therapeutics' Other financing activities stood at $275000.0 in 2023, then surged by 123879.64% to $340.9 million in 2024, then tumbled by 99.42% to $2.0 million in 2025, then tumbled by 87.77% to $243000.0 in 2026.
- Business Quant data shows KYTX's Other financing activities at $243000.0 in Q1 2026, $2.0 million in Q4 2025, and -$3000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Kyverna Therapeutics | 440.57 Mn | 440.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 243,000.00 |
| Mar 31, 2026 | 243,000.00 |
| Dec 31, 2025 | 1.99 Mn |
| Dec 31, 2025 | 1.99 Mn |
| Jun 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | 340.94 Mn |
| Dec 31, 2024 | 340.94 Mn |
| Sep 30, 2024 | 90,000.00 |
| Sep 30, 2024 | 90,000.00 |
| Jun 30, 2024 | -341.03 Mn |
| Jun 30, 2024 | -341.03 Mn |
| Mar 31, 2024 | 341.17 Mn |
| Mar 31, 2024 | 341.17 Mn |
| Dec 31, 2023 | 275,000.00 |
| Dec 31, 2023 | 275,000.00 |
| Sep 30, 2023 | 310,000.00 |
| Sep 30, 2023 | 310,000.00 |